Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | ADH1B | P00325 | 1/20 | 0.31 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1424706 | 1.00 | EPHX1 (0.35) | EPHX1HTR2CSLC6A4GAATSHR | |
| SCHEMBL4971663 | 0.98 | EPHX1 (0.33) | EPHX1HTR2CSLC6A4GAATSHR | |
| SCHEMBL4971669 | 0.98 | EPHX1 (0.33) | EPHX1HTR2CSLC6A4GAATSHR | |
| SCHEMBL1607958 | 0.85 | EPHX1 (0.35) | EPHX1HTR2CSLC6A4GAATSHR | |
| SCHEMBL4972581 | 0.84 | GAA (0.36) | EPHX1GAATSHRCTSSCTSK | |
| SCHEMBL4972576 | 0.84 | GAA (0.36) | EPHX1GAATSHRCTSSCTSK | |
| SCHEMBL4971964 | 0.84 | ASGR1 (0.30) | — | |
| SCHEMBL4971967 | 0.84 | ASGR1 (0.30) | — | |
| SCHEMBL4971462 | 0.84 | GAA (0.36) | EPHX1GAATSHRCTSSCTSK | |
| SCHEMBL4971467 | 0.84 | GAA (0.36) | EPHX1GAATSHRCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190038611-A1 | Novel CYP34A-Specific Inhibitors and Methods of Using Same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-02-07 | — | — | US | disclosed |
| WO-2008156832-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-5346887-A | Mixture of tripeptide renin inhibitor and steroid antiinflammatory agent | ABBOTT LABORATORIES (US) | 1994-09-13 | — | — | US | disclosed |
| EP-0229667-B1 | Peptidylaminodiols | ABBOTT LAB (US) | 1994-07-13 | — | — | EP | disclosed |
| US-5268374-A | Containing both amide and hydroxy groups | ABBOTT LABORATORIES (US) | 1993-12-07 | — | — | US | disclosed |
| US-5214129-A | Amidation of a protected amino acid by an di-O-protected dihydroxy-containing amine and coupling with a carboxylic acid; deprotecting; renin inhibitors; hypotensive agents | ABBOTT LABORATORIES (US) | 1993-05-25 | — | — | US | disclosed |
| EP-0437508-A4 | NON-PEPTIDE RENIN INHIBITORS | — | 1991-11-06 | — | — | EP | disclosed |
| US-5059589-A | Glaucoma treatment | ABBOTT LABORATORIES (US) | 1991-10-22 | — | — | US | disclosed |
| US-5036051-A | Renin inhibitors | ABBOTT LABORATORIES (US) | 1991-07-30 | — | — | US | disclosed |
| EP-0437508-A1 | NON-PEPTIDE RENIN INHIBITORS | ABBOTT LABORATORIES (US) | 1991-07-24 | — | — | EP | disclosed |
| US-4845079-A | HYPOTENSIVE, RENIN INHIBITION | ABBOTT LABORATORIES | 1989-07-04 | — | — | US | disclosed |
| US-4837204-A | RENIN INHIBITORS; HYPOTENSIVE AGENTS | ABBOTT LABORATORIES (US) | 1989-06-06 | — | — | US | disclosed |
| EP-0311012-A2 | Glaucoma treatment | ABBOTT LABORATORIES (US) | 1989-04-12 | — | — | EP | disclosed |
| EP-0295294-A1 | PEPTIDYLAMINODIOLS | ABBOTT LABORATORIES (US) | 1988-12-21 | — | — | EP | disclosed |
| WO-1988005050-A1 | PEPTIDYLAMINODIOLS | ABBOTT LABORATORIES (US) | 1988-07-14 | — | — | WO | disclosed |
| US-4725584-A | Peptidyl-1-amino-2,4-diols | ABBOTT LABORATORIES (US) | 1988-02-16 | — | — | US | disclosed |
| US-4725583-A | ANTIHYPERTENSIVE | ABBOTT LABORATORIES (US) | 1988-02-16 | — | — | US | disclosed |
| EP-0230266-A2 | Functionalized peptidyl aminodiols and -triols | ABBOTT LABORATORIES (US) | 1987-07-29 | — | — | EP | disclosed |
| EP-0229667-A2 | Peptidylaminodiols | ABBOTT LABORATORIES (US) | 1987-07-22 | — | — | EP | disclosed |
| EP-0189203-A2 | Peptidylaminodiols | ABBOTT LABORATORIES (US) | 1986-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190038611-A1 | Novel CYP34A-Specific Inhibitors and Methods of Using Same | CYP3A43, CYP3A4, CYP4B1 | EPHX1 182/4885HTR2C 2024/4885SLC6A4 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.